Impact Analysis of Covid-19

The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters.

Mucopolysaccharidosis refers to a group of inherited conditions in which the body is unable to properly breakdown mucopolysaccharides, a long chain of sugar molecules that are found in the body. As a result, these sugars build up in cells, blood, and connective tissues, which can lead to several health problems. There are seven forms of mucopolysaccharidosis. Generally, most of the affected people appear healthy at birth and experience a period of normal development, followed by a decline in physical and/or mental function. As the condition progresses, it may affect appearance, physical abilities, organ and system functioning, and in most cases, cognitive development. The underlying genetic cause varies by form. Most cases are inherited in an autosomal recessive manner, although one specific form (Type II) follows an X-linked pattern of inheritance. Treatment is based on the signs and symptoms present in each person.

The global mucopolysaccharidosis (MPS) treatment market is estimated to be valued at US$ 1,566.5 million in 2020 and is expected to exhibit a CAGR of 9.8% over the forecast period (2020-2027).

Figure 1. Global Mucopolysaccharidosis (MPS) Treatment Market Share (%) in Terms of Value, By Region, 2020

Mucopolysaccharidosis (MPS) Treatment  | Coherent Market Insights

Increasing product approvals by regulatory authorities for better treatment outcomes is expected to propel the market growth over the forecast period

Key players operating in the market are focusing on obtaining approvals for their advanced therapeutics and this is expected to drive the market growth over the forecast period. For instance, in June 2019, Biomarine Pharmaceuticals Inc. received approval for its Vimizim (elosulfase alfa) from National Medical Products Administration (NMPA) for the treatment of patients with mucopolysaccharidosis type IVA (MPS IVA), also known as Morquio A syndrome. Vimizim is the first treatment in China approved for this condition.

Adoption of inorganic growth strategies by key players is expected to drive the market growth over the forecast period

Market players are more focused on adoption of inorganic growth strategies such as collaborations and partnerships to strengthen their position in the global mucopolysaccharidosis (MPS) treatment market. For instance, in May 2018, Ultragenyx Pharmaceutical Inc. and Rentschler Fill Solutions, a contract manufacturing organization (CMO) and aseptic fill and finish services expert company, collaborated for the production of injectable Mepsevii (vestronidase alfa), a recombinant form of the human enzyme beta-glucuronidase, to treat patients with mucopolysaccharidosis (MPS) VII, a rare genetic disorder.

request-sample

Mucopolysaccharidosis (MPS) Treatment Market Report Coverage

Report Coverage Details
Base Year: 2019 Market Size in 2019: US$ 1,566.5 Mn
Historical Data for: 2016 to 2019 Forecast Period: 2020 to 2027
Forecast Period 2020 to 2027 CAGR: 9.8% 2027 Value Projection: US$ 3,014.9 Mn
Geographies covered:
  • North America: U.S. and Canada
  • Latin America: Brazil, Argentina, Mexico, and Rest of Latin America
  • Europe: Germany, U.K., Spain, France, Italy, Russia, and Rest of Europe
  • Asia Pacific: China, India, Japan, Australia, South Korea, ASEAN, and Rest of Asia Pacific
  • Middle East: GCC, Israel, and Rest of Middle East
  • Africa: South Africa, North Africa, and Central Africa
Segments covered:
  • By Treatment: Enzyme Replacement Therapy, Stem Cell Therapy.
  • By MPS Type: MPS-I, MPS-II, MPS-IV, MPS-VI, MPS-VII, Others (MPS-III and MPS-IX).
  • By End User: Hospitals, Specialty Clinics, Others.
Companies covered:

Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

Growth Drivers:
  • Increasing product approvals by regulatory authorities
  • Adoption of inorganic growth strategies by key players
Restraints & Challenges:
  • High cost of therapeutics coupled with poor diagnosis

Global Mucopolysaccharidosis (MPS) Treatment Market – Impact of Coronavirus (Covid-19) Pandemic

The coronavirus disease (COVID-19) pandemic is the most recent outbreak, which was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared coronavirus disease (COVID-19) as a pandemic on March 11, 2020.

According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, around 27 million cases and 900,000 deaths due to coronavirus disease (COVID-19) were reported on September 06, 2020 across the globe.

According to the Coronavirus Disease (COVID-19) Weekly Epidemiological Update by the World Health Organization, the coronavirus disease (COVID-19) cases in different regions reported on September 06, 2020 are as follows:

WHO Regions New cases in last 7 days Cumulative cases
The Americas 862,478 14,001,390
South-east Asia 616,795 4,689,943
Europe 247,125 4,475,267
Africa 38,639 1,083,152
Eastern Mediterranean 92,699 1,996,246
Western Pacific 28,907 516,478

COVID-19 can affect the economy in three main ways; by directly affecting production and demand, by creating disruptions in distribution channels, and through its financial impact on firms and financial markets. Due to nationwide lockdowns, several countries such as China, India, Saudi Arabia, UAE, Egypt, and others are facing problems with regards to transportation of products and raw materials from one place to another, which is expected to limit the market growth during the forecast period.

Mucopolysaccharidosis (MPS) Treatment Market: Restraints

High cost of therapeutics coupled with poor diagnosis are expected to hinder growth of the global mucopolysaccharidosis (MPS) treatment market during the forecast period. Therapeutics for MPS treatment include Vimizin (elosulfase alfa), which is administered for the treatment of MPS IV (Morquio Syndrome) and which, at the time of launch in the market, was estimated to cost US$ 380,000 for annual treatment. Hence, due to the high cost of treatment, patients in the emerging economies such as India cannot afford these therapeutics.

Another key limiting factor is the delay associated with the diagnosis of mucopolysaccharidosis. For instance, according to the study published in 2018, in the Orphanet Journal of Rare Diseases, there is a failure in diagnosis of the two ultra-orphan diseases of mucopolysaccharidosis type I and mucopolysaccharidosis type III.

Key Players

Major players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.

Currently available therapeutics such as Elaprase and Aldurazyme are not able to appropriately address the neurological symptoms and complications of patients suffering from mucopolysaccharidosis (MPS), as these drugs are not capable of crossing blood brain barrier, a key requirement for effective management of mucopolysaccharidosis (MPS) disorder.

The neurological symptoms associated with mucopolysaccharidosis (MPS) disorder are severely disabling. The therapeutics used currently are not able to treat the neurological symptoms, thus a significant proportion of the population is in need of appropriate treatment. This is expected to propel demand for effective therapeutics, which aid in the management of all types of symptoms of mucopolysaccharidosis (MPS). This is expected to drive growth of the MPS treatment market during the forecast period.

Market Dynamics

Market players are focusing on various inorganic growth strategies such as collaborations and partnerships in order to develop no cost testing programs for patients with mucopolysaccharidosis (MPS), which is expected to boost growth of the global mucopolysaccharidosis (MPS) treatment market. For instance, in October 2018, Sanofi Genzyme and PerkinElmer, Inc. collaborated in order to develop a 'Lantern Project', to provide a no-cost testing program for patients in the U.S. and who suffer from specific types of lysosomal storage disorders (LSDs). Therefore, the Latern Project will arrange screening as well as confirmatory DNA testing and phlebotomy services for the patients suspected to be suffering from Gaucher disease, Fabry disease, Pompe disease, mucopolysaccharidosis type I (MPS I) or acid sphingomyelinase deficiency (ASMD), also known as Niemann-Pick disease types A and B.

Key features of the study:

  • This report provides in-depth analysis of the global mucopolysaccharidosis (MPS) treatment market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2020–2027), considering 2019 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends,  regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global mucopolysaccharidosis (MPS) treatment market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
  • Key companies covered as a part of this study include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • The global mucopolysaccharidosis (MPS) treatment market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global mucopolysaccharidosis (MPS) treatment market.

Detailed Segmentation:

  • Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment:
    • Enzyme Replacement Therapy
    • Stem Cell Therapy
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type:
    • MPS-I
    • MPS-II
    • MPS-IV
    • MPS-VI
    • MPS-VII
    • Others (MPS-III and MPS-IX)
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By End User:
    • Hospitals
    • Specialty Clinics
    • Others
  • Global Mucopolysaccharidosis (MPS) Treatment Market, By Region:
    • North America
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • U.S.
        • Canada
    • Latin America
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country:
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others  
      • By Country:
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • By Treatment:
        • Enzyme Replacement Therapy
        • Stem Cell Therapy
      • By MPS Type
        • MPS-I
        • MPS-II
        • MPS-IV
        • MPS-VI
        • MPS-VII
        • Others (MPS-III and MPS-IX)
      • By End User:
        • Hospitals
        • Specialty Clinics
        • Others
      • By Country/Region:
        • South Africa
        • Central Africa
        • North Africa
  • Company Profiles
    • Takeda Pharmaceutical Company Limited*
      • Company Overview
      • Material Portfolio
      • Financial Performance
      • Key Highlights
      • Market Strategies
    • BioMarin Pharmaceuticals, Inc.
    • Ultragenyx Pharmaceutical Inc.
    • Sarepta Therapeutics
    • Abeona Therapeutics Inc.
    • Eloxx Pharmaceuticals
    • Esteve
    • Immusoft Corporation
    • Inventiva
    • GC Pharma
    • JCR Pharmaceuticals Co Ltd.
    • RegenxBio Inc.
    • Sangamo Therapeutics, Inc.
    • Bioasis Technologies Inc.
    • Paradigm Biopharmaceuticals Ltd.

“*” marked represents similar segmentation in other categories in the respective section.

Table of Contents

  1. Research Objectives and Assumptions
    • Research Objectives
    • Assumptions
    • Abbreviations
  2. Market Purview
    • Report Description
      • Market Definition and Scope
    • Executive Summary
      • Market Snippet, By Treatment
      • Market Snippet, By MPS Type
      • Market Snippet, By End User
      • Market Snippet, By Region
    • Coherent Opportunity Map (COM)
  3. Market Dynamics, Regulations, and Trends Analysis
    • Market Dynamics
      • Drivers
      • Restraints
      • Market Opportunities
    • Impact Analysis
    • Key Developments
    • PEST Analysis
  4. Global Mucopolysaccharidosis (MPS) Treatment Market – Impact of Coronavirus (Covid-19) Pandemic
    • During-COVID 19 Market Analysis
    • Post-COVID 19 Market Analysis
    • Key Developments
  5. Global Mucopolysaccharidosis (MPS) Treatment Market, By Treatment, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Enzyme Replacement Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Stem Cell Therapy
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  6. Global Mucopolysaccharidosis (MPS) Treatment Market, By MPS Type, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • MPS-I
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • MPS-II
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • MPS-IV
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • MPS-VI
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • MPS-VII
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others (MPS-III and MPS-IX)
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  7. Global Mucopolysaccharidosis (MPS) Treatment Market, By End User, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, 2017 – 2027
      • Segment Trends
    • Hospitals
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Specialty Clinics
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
    • Others  
      • Introduction
      • Market Size and Forecast, and Y-o-Y Growth, 2016 – 2027, (US$ Mn)
  8. Global Mucopolysaccharidosis (MPS) Treatment Market, By Region, 2016 – 2027, (US$ Mn)
    • Introduction
      • Market Share Analysis, By Region, 2020 and 2027 (%)
      • Y-o-Y Growth Analysis, For Regions, 2017–2027
    • North America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • U.S.
        • Canada
    • Latin America
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Brazil
        • Mexico
        • Argentina
        • Rest of Latin America
    • Europe
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • Germany
        • U.K.
        • France
        • Italy
        • Spain
        • Russia
        • Rest of Europe
    • Asia Pacific
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • China
        • India
        • Japan
        • Australia
        • South Korea
        • ASEAN
        • Rest of Asia Pacific
    • Middle East
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country, 2016 – 2027, (US$ Mn)
        • GCC
        • Israel
        • Rest of Middle East
    • Africa
      • Market Size and Forecast, By Treatment, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By MPS Type, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By End User, 2016 – 2027, (US$ Mn)
      • Market Size and Forecast, By Country/Region, 2016 – 2027, (US$ Mn)
        • South Africa
        • Central Africa
        • North Africa
  9. Competitive Landscape
    • Heat Map Analysis
    • Market Share Analysis
      • Takeda Pharmaceutical Company Limited
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • BioMarin Pharmaceuticals, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Ultragenyx Pharmaceutical Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sarepta Therapeutics
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Abeona Therapeutics Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Eloxx Pharmaceuticals
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Esteve
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Immusoft Corporation
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Inventiva
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • GC Pharma
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • JCR Pharmaceuticals Co Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • RegenxBio Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Sangamo Therapeutics, Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Bioasis Technologies Inc.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
      • Paradigm Biopharmaceuticals Ltd.
        • Company Overview
        • Device Portfolio
        • Financial Overview
        • Key Highlights
        • Market Strategies
    • Analyst Views
  10. Section
    • References
    • Research Methodology
    • About us and Sales Contact

*Browse 35 market data tables and 34 figures on "Mucopolysaccharidosis (MPS) Treatment Market” - Global forecast to 2027

Frequently Asked Questions

The global mucopolysaccharidosis (MPS) treatment market size is estimated to surpass US$ 3,014.9 million by 2027.
The global mucopolysaccharidosis (MPS) treatment market is expected to register a CAGR of 9.8% during the forecast period (2020-2027).
Increasing product approvals by regulatory authorities and adoption of inorganic growth strategies by key players are driving the global mucopolysaccharidosis (MPS) treatment market growth.
The enzyme replacement therapy segment is estimated to hold major market share in 2020, owing to increasing approval for enzyme replacement therapy for mucopolysaccharidosis (MPS) treatment.
Major factors hampering growth of the market are high cost of therapeutics coupled with poor diagnosis.
Major players operating in the global mucopolysaccharidosis (MPS) treatment market include Takeda Pharmaceutical Company Limited, BioMarin Pharmaceuticals, Inc., Ultragenyx Pharmaceutical Inc., Sarepta Therapeutics, Abeona Therapeutics Inc., Eloxx Pharmaceuticals, Esteve, Immusoft Corporation, Inventiva, GC Pharma, JCR Pharmaceuticals Co Ltd., RegenxBio Inc., Sangamo Therapeutics, Inc., Bioasis Technologies Inc., and Paradigm Biopharmaceuticals Ltd.
Existing Clientele

Joining thousands of companies around the world committed to making the Excellent Business Solutions.

View All Our Clients

Our Trusted Patner